0 Beoordelingen
ID

30011

Beschrijving

Study ID: 100480, 759346/004 & 100791 Clinical Study ID: 100480, 759346/004 & 100791 Study Title: A phase III, partially double blind, randomized, controlled primary vaccination study to assess the reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Tritanrix-HepB/Hib-MenAC vaccine as compared to Tritanrix-HepB/Hib2.5 + Meningitec™ when administered to healthy infants at 6, 10, 14 weeks of age, who have received a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine Trade Name: Tritanrix HepB/Hiberix Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis Documentation part: Visit 1, Day 0, HBV Birth Dose

Trefwoorden

Versies (2)
  1. 10-07-17 10-07-17 -
  2. 04-05-18 04-05-18 - Sarah Riepenhausen
Houder van rechten

GlaxoSmithKline

Geüploaded op

4 mei 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

  • Nieuwste
  • Oudste
  • Populair
  • Nieuwste
    • Nieuwste
    • Oudste
    • Populair

    Geen commentaren

    U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

    Tritanrix-HepB/Hib-MenAC vaccine compared to Tritanrix-HepB/Hiberix and Meningitec Visit 1 759346/004

    Engels

    Visit 1 Tritanrix-HepB/Hib-MenAC vaccine compared to Tritanrix-HepB/Hiberix and Meningitec 759346/004

    1 Formulieren  
    Informed Consent
    Beschrijving

    Informed Consent

    Alias
    UMLS CUI-1
    C0021430 (Informed Consent)
    UMLS CUI-2
    C0042210 (Vaccines)
    SNOMED
    787859002
    LOINC
    LA20283-0
    Subject Number
    Beschrijving

    Subject Number

    Datatype

    text

    Alias
    UMLS CUI [1]
    C2348585 (Clinical Trial Subject Unique Identifier)
    Date of Visit
    Beschrijving

    Date of Visit

    Datatype

    date

    Alias
    UMLS CUI [1]
    C1320303 (Date of visit)
    SNOMED
    406543005
    Informed Consent Date
    Beschrijving

    I certify that Informed Consent has been obtained prior to any study procedure.

    Datatype

    time

    Alias
    UMLS CUI [1,1]
    C0021430 (Informed Consent)
    UMLS CUI [1,2]
    C0011008 (Date in time)
    SNOMED
    410671006
    Demographics
    Beschrijving

    Demographics

    Alias
    UMLS CUI-1
    C0011298 (Demography)
    LOINC
    LP204151-7
    UMLS CUI-2
    C0042210 (Vaccines)
    SNOMED
    787859002
    LOINC
    LA20283-0
    Center number
    Beschrijving

    Center number

    Datatype

    text

    Alias
    UMLS CUI [1,1]
    C1301943 (Institution name)
    SNOMED
    398321007
    UMLS CUI [1,2]
    C0600091 (Identifier)
    SNOMED
    118522005
    LOINC
    LP31795-5
    Date of birth
    Beschrijving

    Date of birth

    Datatype

    date

    Alias
    UMLS CUI [1]
    C0421451 (Patient date of birth)
    SNOMED
    184099003
    LOINC
    LP57552-9
    Gender
    Beschrijving

    Gender

    Datatype

    text

    Alias
    UMLS CUI [1]
    C0079399 (Gender)
    SNOMED
    263495000
    LOINC
    LP61312-2
    Race
    Beschrijving

    Race

    Datatype

    integer

    Alias
    UMLS CUI [1]
    C0034510 (Racial group)
    SNOMED
    415229000
    LOINC
    LP7528-5
    Race, if other please specify
    Beschrijving

    Race

    Datatype

    text

    Alias
    UMLS CUI [1]
    C0034510 (Racial group)
    SNOMED
    415229000
    LOINC
    LP7528-5
    Eligibility Question
    Beschrijving

    Eligibility Question

    Alias
    UMLS CUI-1
    C1516637 (Clinical Trial Eligibility Criteria)
    UMLS CUI-2
    C0042210 (Vaccines)
    SNOMED
    787859002
    LOINC
    LA20283-0
    Did the subject meet all the entry criteria?
    Beschrijving

    If No, please complete below.

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C1516637 (Clinical Trial Eligibility Criteria)
    Inclusion Criteria
    Beschrijving

    Tick the boxes corresponding to any of the inclusion criteria the subject failed

    Datatype

    integer

    Alias
    UMLS CUI [1]
    C1512693 (Inclusion)
    Exclusion Criteria
    Beschrijving

    Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.

    Datatype

    integer

    Alias
    UMLS CUI [1]
    C0680251 (Exclusion Criteria)
    Hepatitis B Vaccine
    Beschrijving

    Hepatitis B Vaccine

    Alias
    UMLS CUI-1
    C2240392 (Hepatitis B Vaccines)
    SNOMED
    871822003
    Has the Hepatitis B vaccine been administered ?
    Beschrijving

    Hepatitis B vaccine

    Datatype

    boolean

    Alias
    UMLS CUI [1,1]
    C2240392 (Hepatitis B Vaccines)
    SNOMED
    871822003
    UMLS CUI [1,2]
    C2368628 (Administration of vaccine)
    Terug naar het begin van de pagina

    Similar models

    Visit 1 Tritanrix-HepB/Hib-MenAC vaccine compared to Tritanrix-HepB/Hiberix and Meningitec 759346/004

    1 Formulieren
    Name
    Type
    Description | Question | Decode (Coded Value)
    Datatype
    Alias
    Item Group
    Informed Consent
    C0021430 (UMLS CUI-1)
    C0042210 (UMLS CUI-2)
    Subject Number
    Item
    Subject Number
    text
    C2348585 (UMLS CUI [1])
    Date of Visit
    Item
    Date of Visit
    date
    C1320303 (UMLS CUI [1])
    Informed Consent Date
    Item
    Informed Consent Date
    time
    C0021430 (UMLS CUI [1,1])
    C0011008 (UMLS CUI [1,2])
    Item Group
    Demographics
    C0011298 (UMLS CUI-1)
    C0042210 (UMLS CUI-2)
    Center number
    Item
    Center number
    text
    C1301943 (UMLS CUI [1,1])
    C0600091 (UMLS CUI [1,2])
    Date of birth
    Item
    Date of birth
    date
    C0421451 (UMLS CUI [1])
    Item
    Gender
    text
    C0079399 (UMLS CUI [1])
    Gender
    Code List
    Gender
    Item
    Race
    integer
    C0034510 (UMLS CUI [1])
    Race
    Code List
    Race
    CL Item
    Black (1)
    CL Item
    Arabic/North African (2)
    CL Item
    White/Caucasian (3)
    CL Item
    East & South East Asian (4)
    CL Item
    South Asian (5)
    CL Item
    Other, please specify (6)
    Race
    Item
    Race, if other please specify
    text
    C0034510 (UMLS CUI [1])
    Item Group
    Eligibility Question
    C1516637 (UMLS CUI-1)
    C0042210 (UMLS CUI-2)
    Did the subject meet all the entry criteria?
    Item
    Did the subject meet all the entry criteria?
    boolean
    C1516637 (UMLS CUI [1])
    Item
    Inclusion Criteria
    integer
    C1512693 (UMLS CUI [1])
    Inclusion Criteria
    Code List
    Inclusion Criteria
    CL Item
    Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study. (1)
    CL Item
    Written informed consent obtained from the parent or guardian of the subject (2)
    CL Item
    Free of obvious health problems as established by medical history and clinical examination before entering into the study. (3)
    CL Item
    Born after a gestation period of 36 to 42 weeks (4)
    CL Item
    A male or female less than or equal to 3 days (72 hours) of age at the time of the birth dose of hepatitis B vaccine. (5)
    Item
    Exclusion Criteria
    integer
    C0680251 (UMLS CUI [1])
    Exclusion Criteria
    Code List
    Exclusion Criteria
    CL Item
    Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. (1)
    CL Item
    A family history of congenital or hereditary immunodeficiency. (2)
    CL Item
    Major congenital defects or serious chronic illness. (3)
    CL Item
    History of any neurologic disorders or seizures. (4)
    CL Item
    Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. (5)
    CL Item
    Acute disease at the time of enrolment (Acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature <37.5°C or rectal temperature <38.0°C). (6)
    CL Item
    Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes. (7)
    Item Group
    Hepatitis B Vaccine
    C2240392 (UMLS CUI-1)
    Hepatitis B vaccine
    Item
    Has the Hepatitis B vaccine been administered ?
    boolean
    C2240392 (UMLS CUI [1,1])
    C2368628 (UMLS CUI [1,2])
    Terug naar het begin van de pagina 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial